Skip to content

Author

Angeliki Margoni

We have 3 of 35 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Myocardial extracellular volume reduction is associated with improved cardiac function after SGLT2 inhibitor therapy in HFpEF

In patients with heart failure with preserved ejection fraction (HFpEF), sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve prognosis and symptoms. To evaluate the short-term effects of SGLT2i on myocardial extracellular volume (ECV) and left ventricular (LV) function in patients with HFpEF and diabetes mellit...

A. Marathonitis, A. Anastasiou, N. Vythoulkas-Biotis et al. · 0 citations
Review Open access Sep 2026

Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology

It is argued that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.

K. Papavassiliou, A. Sofianidi, Angeliki Margoni et al. · 0 citations
Open access Sep 2026

Beyond Sequencing: Integrating MLPA Reveals Hidden Structural PKD2 Variants and Enhances Mutation Detection in a Highly Selected ADPKD Greek Cohort

The findings identify structural PKD2 variation as an under-recognized cause of genetically unresolved late-onset ADPKD and demonstrate that phenotype-guided incorporation of copy number analysis can overcome limitations of NGS alone.

Akrivi Papachristopoulou, Angeliki Margoni, A. Simoudis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.